-+ 0.00%
-+ 0.00%
-+ 0.00%

Kexon Pharmaceuticals (688136.SH): Application for marketing license for polyethylene glycolated human granulocyte stimulating factor injection was accepted

Zhitongcaijing·10/09/2026 13:09:06
Listen to the news

Zhitong Finance App News, Kexing Pharmaceuticals (688136.SH) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration regarding the marketing license application for the drug polyethylene glycolated human granulocyte-stimulating factor injection (“GB-K02” for short). The company's GB-K02 is suitable for patients with non-myeloid malignant tumors to reduce the incidence of infections characterized by febrile neutropenia when receiving myelosuppressive anticancer drugs that are likely to cause clinically significant febrile neutropenia.